The BATF3 Knockout UM-UC-3 Polyclonal Cells consist of a CRISPR/Cas9-edited heterogeneous population of UM-UC-3 human bladder cancer cells with targeted disruption of the BATF3 gene. This polyclonal knockout pool enables loss-of-function studies while retaining the genetic heterogeneity of the parental background, avoiding clonal selection biases.
The UM-UC-3 cell line, derived from a male patient with transitional cell carcinoma, displays epithelial morphology and is widely used as a model for bladder cancer biology. Its well-characterized growth properties and genomic features make it suitable for investigating tumor cell-intrinsic immune mechanisms and therapeutic responses.
BATF3 encodes a basic leucine zipper transcription factor essential for the development of conventional type 1 dendritic cells (cDC1), which specialize in cross-presentation to CD8+ T cells. Its activity is induced by upstream regulators including interferon-alpha/beta, IRF8, and PU.1, and is further modulated by Toll-like receptor (TLR) ligands such as CpG and poly I:C. Upon activation, BATF3 cooperates with AP-1 family members like BATF and Jun proteins to drive expression of downstream targets including IL-12, ID2, XCR1, and Clec9a, as well as components of the cross-presentation machinery. This transcriptional network is critical for type I interferon signaling and effective antitumor immunity.
Disruption of BATF3 in UM-UC-3 cells impairs the transcriptional programs required for cross-presentation and immune cell interaction, providing a model to study how loss of BATF3 alters cytokine secretion, surface marker expression, and tumor-immune cross-talk. This system is particularly relevant for investigating immune evasion mechanisms in bladder cancer and for evaluating strategies to restore or bypass defective DC-mediated antitumor responses.
These polyclonal knockout cells are suited for flow cytometry analysis of cDC1 markers (XCR1, Clec9a), RT-qPCR profiling of BATF3 target genes, and western blotting for BATF3 protein. Co-culture assays with T cells and ELISA for IL-12 secretion allow functional assessment of cross-presentation capacity. Additional applications include tumor growth studies in vivo and screening of adjuvants targeting TLR or interferon pathways. This tool supports research in dendritic cell biology, cancer immunotherapy, and bladder tumor immunology. For additional information, please contact Ascent Research.
